BELLEVUE, Wash., Oct. 7, 2009 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has received a Buy recommendation from Konrad Kuhn, editor and head analyst of the KonLin Newsletter.
